Nafamostat Mesylate

Catalog No.S1386

Nafamostat Mesylate is an anticoagulant.Phase 4.

Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
USD 310 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nafamostat Mesylate Chemical Structure

Nafamostat Mesylate Chemical Structure
Molecular Weight: 539.58

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Nafamostat Mesylate is available in the following compound libraries:

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Inhibitors
  • Research Area

Product Description

Biological Activity

Nafamostat is an anticoagulant. Broad spectrum serine protease inhibitor. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma. [1]

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01761994 Completed Acute Kidney Injury Yonsei University|SK Chemicals Co.,Ltd. 2007-09 Phase 4
NCT01001403 Completed Liver Transplantation|Postreperfusion Syndrome Seoul National University Hospital 2009-03 Phase 4
NCT01486485 Recruiting Acute Kidney Injury Seoul National University Hospital|SK Chemicals Co.,Ltd. 2012-03 Phase 3

Chemical Information

Download Nafamostat Mesylate SDF
Molecular Weight (MW) 539.58
Formula

C19H17N5O2.2CH4O3S

CAS No. 82956-11-4
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms Futhan, FUT-175
Solubility (25°C) * In vitro DMSO 20 mg/mL (37 mM)
Water 53 mg/mL (98 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-carbamimidoylnaphthalen-2-yl 4-guanidinobenzoate dimethanesulfonate

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.53958 5.3958 10.7916 16.1874

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Inhibitors

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Epoxomicin

    Epoxomicin is a selective proteasome inhibitor with anti-inflammatory activity, inhibits primarily the CH-L activity of the 20S proteasome, while T-L and PGPH catalytic activities are also inhibited at 100- and 1000-fold reduced rate.

    Features:Epoxomicin is a natural product isolated from an Actinomycetes species.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • MLN2238

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • CEP-18770 (Delanzomib)

    CEP-18770 is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.

  • Nafamostat Mesylate

    Nafamostat Mesylate is an anticoagulant.Phase 4.

Recently Viewed Items

Tags: buy Nafamostat Mesylate | Nafamostat Mesylate ic50 | Nafamostat Mesylate price | Nafamostat Mesylate cost | Nafamostat Mesylate solubility dmso | Nafamostat Mesylate purchase | Nafamostat Mesylate manufacturer | Nafamostat Mesylate research buy | Nafamostat Mesylate order | Nafamostat Mesylate mouse | Nafamostat Mesylate chemical structure | Nafamostat Mesylate mw | Nafamostat Mesylate molecular weight | Nafamostat Mesylate datasheet | Nafamostat Mesylate supplier | Nafamostat Mesylate in vitro | Nafamostat Mesylate cell line | Nafamostat Mesylate concentration | Nafamostat Mesylate nmr
Contact Us